'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Dishman Carbogen Amcis Limited
DCAL (NSE) · DCAL (BSE 540701) · ISIN INE385W01011 · Pharmaceuticals · Est. 2007 · listed 2017 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹57.08 cr and profit after tax −₹23.91 cr. Revenue was 9.2% lower than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹57.08 cr | −₹23.91 cr | −1.52 | 14 Aug 2026 |
| Q4 FY26 standalone | ₹68.72 cr | −₹4.34 cr | −0.28 | 19 May 2026 |
| Q3 FY26 standalone | ₹39.68 cr | −₹23.13 cr | −1.47 | 3 Feb 2026 |
| Q2 FY26 standalone | ₹60.3 cr | −₹13.6 cr | −0.87 | 4 Nov 2025 |
| Q1 FY26 standalone | ₹62.86 cr | ₹2.67 cr | 0.17 | 12 Aug 2025 |
| Q4 FY25 standalone | ₹106.1 cr | −₹7.37 cr | −0.47 | 22 May 2025 |
| Q3 FY25 standalone | ₹293.74 cr | −₹2.5 cr | −0.16 | 13 Feb 2025 |
| Q2 FY25 standalone | ₹196.7 cr | ₹10.78 cr | 0.69 | 14 Nov 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹3,882.23 cr | ₹630.62 cr | ₹5,126.04 cr |
| 30 Sep 2025 standalone | ₹3,970.67 cr | ₹676.28 cr | ₹5,148.1 cr |
| 31 Mar 2025 standalone | ₹4,030.48 cr | ₹678.56 cr | ₹5,122.35 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 59.32% | 6.97% | 1.66% | 40.68% |
Latest filings
- Dishman Carbogen Amcis Limited has informed the Exchange regarding Outcome of Board Meeting held on October 07, 2026. 7 October 2026 · NSE
- Annual Report FY2025-26 (New) 5 September 2026 · NSE
- Dishman Carbogen Amcis Limited has informed the Exchange about Transcript 21 August 2026 · NSE
- Dishman Carbogen Amcis Limited has informed the Exchange about Link of Recording 17 August 2026 · NSE
- Dishman Carbogen Amcis Limited has informed the Exchange about Investor Presentation 17 August 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 7 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.